Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | EP300 | Q09472 | 1/20 | 0.44 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8255367 | 0.78 | CASP3 (0.52) | CMA1HDAC6TP53MAPTMEN1 | |
| SCHEMBL29173729 | 0.76 | HDAC1 (0.63) | CMA1HDAC6MAPTLMNAMEN1 | |
| SCHEMBL3408919 | 0.76 | CASP3 (0.52) | CMA1HDAC6TP53MAPTMEN1 | |
| SCHEMBL14991264 | 0.75 | GAA (0.47) | CMA1TP53MAPTLMNAHTT | |
| SCHEMBL11187851 | 0.75 | TSHR (0.41) | CMA1TP53MAPTLMNAHTT | |
| SCHEMBL6706100 | 0.73 | MMP13 (0.42) | MAPTLMNAHTTNPSR1SIGMAR1 | |
| SCHEMBL3944389 | 0.72 | HDAC6 (0.46) | CMA1HDAC6MAPTLMNAHTT | |
| SCHEMBL21310500 | 0.72 | CHRM5 (0.44) | CMA1TP53MAPTMEN1KMT2A | |
| SCHEMBL578360 | 0.71 | MEN1 (0.57) | CMA1MAPTMEN1KMT2ACASP3 | |
| SCHEMBL30068092 | 0.71 | MEN1 (0.57) | CMA1MAPTMEN1KMT2ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049503-B1 | QUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES AS P38 KINASE INHIBITORS | AMGEN INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-7935709-B2 | 2-quinazolinone compounds and methods of use | AMGEN INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20080032973-A1 | 2-Quinazolinone compounds and methods of use | AMGEN INC. (US) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032973-A1 | 2-Quinazolinone compounds and methods of use | MAP3K1, MAP3K2, MAP3K7 | CMA1 628/4885HDAC6 1955/4885TP53 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.